Direct renin inhibitor (aliskiren)and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy - APSHA

• Conditions: Essential hypertension.; MedDRA version: 9.1Level: LLTClassification code 10059238; MedDRA version: 9.1Level: LLTClassification code 10007692

• Registration Number: EUCTR2009-016902-17-IT
• Lead Sponsor: AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03-11
• Last Update Posted: 11 September 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patient eligible for surgical carotid endoarterectomy (urgencies excluded), stable treatment with at least two anti-hypertensive drugs, written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
;
Patient eligible for surgical carotid endoarterectomy (urgencies excluded), stable treatment with at least two anti-hypertensive drugs, written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Non menopausal women, severe (stage 3) hypertension, creatinine clearance < 30 ml/min, uncontrolled diabetes mellitus, heart failure NYHA class 3 or 4, acute cardiovascular events in the last 3 months, bilateral > 50% carotid stenoses.
;
Non menopausal women, severe (stage 3) hypertension, creatinine clearance < 30 ml/min, uncontrolled diabetes mellitus, heart failure NYHA class 3 or 4, acute cardiovascular events in the last 3 months, bilateral > 50% carotid stenoses.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified